Using HIPEC with chemotherapy before surgery for advanced gastric cancer
Official title: A Randomized, Multicenter Clinical Trial Comparing the Combination of Perioperative FLOT Chemotherapy and Preoperative Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Plus Gastrectomy to Perioperative FLOT Chemotherapy and Gastrectomy Alone in Patients With Advanced Gastric Cancer at High Risk of Peritoneal Recurrence
Run by Jagiellonian University · NCT04597294 · Data updated 2026-11-12
This study is testing if adding a special heated chemotherapy treatment before surgery can help people with advanced stomach cancer avoid cancer returning in their abdomen.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | Jagiellonian University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Krakow, Lesser Poland Voivodship) |
| Status | Recruiting |
| Started | August 1, 2021 |
| Main results expected | January 2026 |
| Study ends | December 2026 |
| Registry record updated | March 6, 2024 |
| Trial ID | NCT04597294 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-75 with histopathologically confirmed advanced gastric cancer and no distant metastases.
✕Probably not a fit
Patients over 75 years old or those with poor general health or other significant health issues may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the effectiveness of combining hyperthermic intraperitoneal chemotherapy (HIPEC) with FLOT chemotherapy in patients with advanced gastric cancer who are at high risk for peritoneal metastases. In this randomized, multicenter study, 598 participants will be assigned to receive either HIPEC plus surgery or surgery alone, both followed by additional FLOT chemotherapy. The primary goal is to assess the rate of peritoneal recurrence within six months post-surgery, with long-term follow-up extending to five years to evaluate overall survival and recurrence rates.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the risk of peritoneal recurrence and improve survival rates for patients with advanced gastric cancer.
How similar studies have gone: Previous studies have shown promising results with HIPEC in various cancers, suggesting potential success for this novel application in gastric cancer.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Gastric cancer confirmed histopathologically in tumor specimens. * Age 18-75 years. * Advanced gastric cancer cT3 / cT4a / N0-3b. * No distant metastases on computed tomography (CT) scan of the chest, abdomen and pelvis (cM0). * Written consent to participate in the study. Exclusion Criteria: * No clear histopathological confirmation of gastric cancer. * Age \> 75 years. * Poor general condition (Performance Status 3 or more on the Eastern Cooperative Oncology Group (ECOG)/World Health Organization scale). * Previous abdominal surgery (including oncological surgery), other than laparoscopic cholecystectomy or appendectomy (open or laparoscopic). * Pregnancy and lactation. * Refusal to participate or an inability to provide written consent. * Coexisting cancer in another location. * Systemic treatment or radiotherapy for another cancer. * Dysphagia requiring surgical treatment (gastric resection or nutritional jejunostomy) before starting neoadjuvant treatment and indication for accelerated surgery for other reasons. * Disqualification for perioperative FLOT4 chemotherapy as decided by a multi-specialist consultation.
Where it's running
-
Department of General, Oncological, Gastroenterological Surgery and Transplantology
Krakow, Lesser Poland Voivodship, Poland Recruiting
Study contacts
- Study coordinator: Piotr Richter, Professor
- Email: piotr.richter@uj.edu.pl
- Phone: +48124002400
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer
This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.